Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EIF4EBP1 | Q13541 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305604 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2314932 | 0.81 | SCD (0.66) | SMN1; SMN2MAPK1PPARGPDE5AMMP13 | |
| SCHEMBL6301496 | 0.79 | PPARG (0.57) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL262559 | 0.78 | LMNA (0.52) | SMN1; SMN2MAPK1HTTPPARGMMP13 | |
| SCHEMBL23520500 | 0.76 | MMP13 (0.65) | MMP13 | |
| SCHEMBL401474 | 0.74 | MBOAT4 (0.46) | CYP3A4TSHRPDE5ARAB9AKMT2A | |
| SCHEMBL7508385 | 0.73 | ATM (0.69) | SMN1; SMN2CYP3A4CYP2C19HTTRAB9A | |
| SCHEMBL2315906 | 0.73 | HDAC6 (0.59) | SMN1; SMN2PPARGPDE5AMMP13STAT1 | |
| SCHEMBL1513333 | 0.72 | PTGDR (0.48) | EIF4EBP1PPARGNR4A2 | |
| SCHEMBL5881557 | 0.72 | SLC22A12 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | SMN1; SMN2 186/4885CYP1A2 1473/4885CYP3A4 2770/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | SMN1; SMN2 1017/4885CYP1A2 979/4885CYP3A4 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.